Sentences with phrase «global program development»

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

The resulting data will help shape the details of the program, and «allow us to focus resources on where the greatest impact will be,» says Bob Annibale, Global Director of Community Development at Citigroup.

A new paper from the Center for Global Development finds that from the early 1990s to 2010, the H - 1B visa program resulted in net gains for the United States and India.

Stanford, whose program was unveiled in the fall of 2007, put more critical thinking, leadership development, global content and a required international experience into its MBA.

She is an Australia Day Ambassador for Western Australia, sits on the Board of Directors of the Museum of Freedom and Tolerance Western Australia, and is the Founding Director of the Whande Group, a premier diversity consultancy and program development organisation specialising in global diversity.

Professor George is former faculty chair of HBS's executive education program Authentic Leadership Development and co-chair of Leading Global Enterprises.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Broadspire employs a team of more than 1,500 professionals worldwide and offers a competitive salary and benefits package to eligible staff, including ample professional development opportunities, career - advancement programs, global relocation opportunities, medical coverage, and tuition reimbursement.

He is currently the Director, New Program Development of R / GA Ventures where he works with global brands to develop in house, partner and accelerator programs.

The Carnegie Europe Program in Washington provides insight and analysis on political and security developments within Europe, transatlantic relations, and Europe's global role.

The program has also partnered with The Working Group, a top web and mobile development shop in Toronto; Media Profile, one of Canada's most successful public relations firms; Global Accelerator Network, an international alliance of organizations that operate accelerator programs, championed by TechStars; and Postmedia Network Inc., the largest publisher of English daily newspapers in Canada.

Austin is actively engaged in the Company's 5by20 Global initiative to empower five million women entrepreneurs by 2020 and is a past participant in Coca - Cola's Women in Leadership Program, which is designed to provide key female talent an opportunity for accelerated development.

Our technology expertise, brand capital, and access to our global network via our business development programs help Intel Capital entrepreneurs build lasting success.

«Our Centers of Excellence program provide members with a unique forum to start development opportunities for minority businesses and corporate members alike,» said NMSDC Chairman Joe Hinrichs, who also is president, Global Operations at Ford Motor Company.

PNC Equipment Finance's Vendor Program Business Development team customize sales finance programs for global manufacturers, distributors, software and service providers that assist in generating incremental revenue that enhance margins and improve market share.

Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; the risks and increased costs associated with operating internationally; our expansion into and investments in new markets; breaches in data security or other disturbances to our information technology and other networks; the spread of epidemics and viral outbreaks; adverse incidents involving cruise ships; changes in fuel prices and / or other cruise operating costs; any impairment of our tradenames or goodwill; our hedging strategies; our inability to obtain adequate insurance coverage; our substantial indebtedness, including the ability to raise additional capital to fund our operations, and to generate the necessary amount of cash to service our existing debt; restrictions in the agreements governing our indebtedness that limit our flexibility in operating our business; the significant portion of our assets pledged as collateral under our existing debt agreements and the ability of our creditors to accelerate the repayment of our indebtedness; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our inability to recruit or retain qualified personnel or the loss of key personnel; future changes relating to how external distribution channels sell and market our cruises; our reliance on third parties to provide hotel management services to certain ships and certain other services; delays in our shipbuilding program and ship repairs, maintenance and refurbishments; future increases in the price of, or major changes or reduction in, commercial airline services; seasonal variations in passenger fare rates and occupancy levels at different times of the year; our ability to keep pace with developments in technology; amendments to our collective bargaining agreements for crew members and other employee relation issues; the continued availability of attractive port destinations; pending or threatened litigation, investigations and enforcement actions; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under «Risk Factors» in our most recently filed Annual Report on Form 10 - K and subsequent filings by the Company with the Securities and Exchange Commission.

Back row standing left to right: Tanya Penny, Vice President, Verizon; Carolyn Walsh, Vice President, Southwest Region, UPS; Michael McGranaghan, Vice President and Chief Procurement Officer, Johnson & Johnson; Scott Buchanan, VP, PepsiCo Global Procurement, PepsiCo Inc.; Robert McCormes - Ballou, Director, Vendor Development & Diversity, Office Depot; Ingrid Saunders Jones, Senior Vice President, Corporate External Affairs and Chair of the Coca - Cola Foundation; John Wilder, Chairman and CEO, TXU; Karen Sclafani, Senior Vice President and General Counsel, Avis Budget Group, Inc.; Michael Robinson, Program Director, Global Supplier Diversity, IBM Corporation; John Jefferson, Director of Diversity, Shell Oil Company; and Jean Baderschneider, Vice President, Global Procurement, Exxon Mobil Corporation.

We are grateful for America's global development and diplomacy programs that have been instrumental in saving lives, safeguarding religious liberties, and keeping America safe and secure.

The alternative to the top - down development programs of both global capitalism and state socialism is bottom - up development.

- «Programming, advisory services, technical assistance, training and capacity development: carrying out catalytic, targeted and multisectoral programming; providing advisory services worldwide for the effective implementation of the commitments and norms adopted at the global level in the area of gender...Programming, advisory services, technical assistance, training and capacity development: carrying out catalytic, targeted and multisectoral programming; providing advisory services worldwide for the effective implementation of the commitments and norms adopted at the global level in the area of gender...programming; providing advisory services worldwide for the effective implementation of the commitments and norms adopted at the global level in the area of gender...» [6]

Initially, the bank's program for alleviating global poverty was dominated by a strategy of economic growth, measured primarily in terms of GDP and channeled largely through big projects aimed at infrastructure development that benefited the rich more than the poor.

Stephan's pursuit of justice led him to transition from a successful career in the Fortune 100 sector to Africa, where he directed relief and development programs for nearly a decade before returning to the United States to lead World Relief's global operations.

DuPont Packaging & Industrial Polymers leverages its science and technology know - how through a global development team working with converters, brand owners, retailers and others on packaging programs in the areas of total cost reduction, product protection, environmental stewardship, shelf appeal and convenience.

John Heckman, director of FiveWinds International, said the goals of the program are to development third - party verification options for the Sustainable Winegrowing Program (SWP), maintain California's global leadership position in sustainability and to increase transparency and enhance credibility with key stakehprogram are to development third - party verification options for the Sustainable Winegrowing Program (SWP), maintain California's global leadership position in sustainability and to increase transparency and enhance credibility with key stakehProgram (SWP), maintain California's global leadership position in sustainability and to increase transparency and enhance credibility with key stakeholders.

The Global Rice Science Partnership (GRiSP) or the CGIAR Research Program on Rice, provides a single strategic plan and unique new partnership platform for impact - oriented rice research for development; it is designed to more effectively solve development challenges.

The grant comes from the Global Environmental Facility, an independent financial organization established in 1990 by the World Bank, the United Nations Environment Program, and the United Nations Development Program.

Dr. Schilling galvanized the world coffee industry, worth $ 174 billion dollars per year, to recognize the potentially disastrous vulnerabilities it faced due to the lack of functional, global, open - source research and development programs that create new knowledge and technologies for the benefit of farmers.

The CGIAR Research Program for Rice, known as the Global Rice Science Partnership (GRiSP), is a partnership coordinated by six research - for - development organizations that bring together over 900 partners from the academic, public, private, and civil society sectors with a stake in the rice development sector.

SCOTTSDALE, Ariz., May 5, 2016 / PRNewswire / — RiceBran Technologies (NASDAQ: RIBT and RIBTW)(the «Company» or «RBT»), a global leader in the production and marketing of value added products derived from rice bran, announced today that it has entered into two agreements: a Memorandum of Understanding (MOU) with non-profit The Jack Brewer Foundation (JBF Worldwide) to develop rice bran based supplemental feeding programs currently assisted by JBF Worldwide at orphanages in Malawi and Haiti; and a business development agreement with Brewer + Associates Consulting, LLC (B+A) to collaborate on the planned launch of a new line of sports nutrition products with a portion of profits earmarked to provide rice bran based meal supplements for feeding programs covered by the MOU.

The next - generation multi-media production company STUDIO RAMSAY has a joint venture with All3Media to develop and produce both unscripted and scripted television shows, creating new formats and innovative programming that includes a scripted arm focused on food - related themes, and development of new talent on a global front.

The Winter Fancy Food Show Trendspotter Panel included Polly Adema, PhD, associate professor and director of graduate Food Studies Program, University of the Pacific SF; Kara Nielsen, vice president, Trends & Marketing, CCD Innovation; Tu David Phu, chef / owner, AN — a Vietnamese Dining Experience; and Joey Wells, American Cheese Society Certified Cheese Professional and Whole Foods Market Global Senior Coordinator overseeing Specialty Cheese Product Innovation & Development.

Through the annual flagship program, World Breastfeeding Week, WABA has made a significant contribution to keeping breastfeeding on the global development agenda.

Programs are supported and implemented by many global partners including the US Agency for International Development (USAID), Save the Children, Laerdal Global Health, Latter - day Saint Charities, and Johnson & Johglobal partners including the US Agency for International Development (USAID), Save the Children, Laerdal Global Health, Latter - day Saint Charities, and Johnson & JohGlobal Health, Latter - day Saint Charities, and Johnson & John son.

Spotlight: Replacement Feeding: Transition to Replacement Feeding by HIV - Positive Women Who Breastfeed is a publication by LINKAGES: Breastfeeding, LAM, Related Complementary Feeding, and Maternal Nutrition Program, and was made possible through support provided to the Academy for Educational Development (AED) by the Bureau for Global Health of the United States Agency for International Development (USAID), under the terms of Cooperative Agreement No.

Breastfeeding and Maternal Nutrition Frequently Asked Questions (FAQ) is a publication by LINKAGES: Breastfeeding, LAM, Related Complementary Feeding, and Maternal Nutrition Program, and was made possible through support provided to the Academy for Educational Development (AED) by the Bureau for Global Health of the United States Agency for International Development (USAID), under the terms of Cooperative Agreement No.

She also played a key role in the initial development of the Global Partners Program.

Learning from Large - Scale Community - Based Programmes to Improve Breastfeeding Practices (2008) Authoring organization (s): World Health Organization (WHO), United Nations Children's Fund (UNICEF), Academy for Educational Development, Africa's Health in 2010 Published: 2008 Summary: Community - based breastfeeding promotion and support is one of the key components of a comprehensive program to improve breastfeeding practices, as outlined in the WHO / UNICEF Global Strategy for Infant and Young Child Feeding.

This FAQ Sheet is a publication by LINKAGES: Breastfeeding, LAM, Complementary Feeding, and Maternal Nutrition Program, and was made possible through support provided to the Academy for Educational Development (AED) by the Bureau for Global Health of the United States Agency for International Development (USAID), under the terms of Cooperative Agreement No.

Abt Associates is a mission - driven, global leader in research and program implementation in the fields of health, social and environmental policy, and international development.

Spotlight: PMTCT: Reducing Mother - to - Child Transmission of HIV among Women who Breastfeed is a publication by LINKAGES: Breastfeeding, LAM, Related Complementary Feeding, and Maternal Nutrition Program, and was made possible through support provided to the Academy for Educational Development (AED) by the Bureau for Global Health of the United States Agency for International Development (USAID), under the terms of Cooperative Agreement No.

The modern economy is a global one that is yours to explore, according to Maryann Stein, director of international programs for the Erie County Industrial Development Agency.

Maggie is a Program Manager with U.S. Agency for International Development (USAID), Global Development Lab.

She was also a 2013 - 15 Executive Branch Fellow at USAID, in the Global Development Lab, where as a fellow and now program manager, she focuses on sourcing, piloting, and scaling science and technology innovations for the developing world as part of a network of universities called the Higher Education Solution Network (HESN).

La Montagne chaired the World Health Organization Task Force on Strategic Planning for the Children's Vaccine Initiative, advised the Pan American Health Organization on programs for vaccine - research implementation, and served as a member of the board for the Global Alliance for Tuberculosis Drug Development.

An internationally - recognized scientist with more than 16 years of experience in translational immunoparasitology research and vaccine development for neglected tropical diseases, Bottazzi's major interest lies in the role of vaccines as control tools integrated into international public and global health programs and initiatives.

«Our findings will inform the development of global population - level interventions to reduce stroke, and how such programs may be tailored to individual regions,» said Yusuf, a professor of medicine of McMaster's Michael G. DeGroote School of Medicine and director of the PHRI.

The Joep Lange Institute was formally announced on Wednesday, along with a new, rotating chair and fellowship program at the Academic Medical Center, where Lange was a professor and founded the Amsterdam Institute for Global Health and Development.

These will be discussed today in New York at a summit on snow leopard conservation convened by the UN Development Programme in conjunction with the Global Snow Leopard and Ecosystem Protection Program.

As former lead of the World Bank's global program for fisheries and aquaculture, he said these indicators could be very useful for institutions like the World Bank, the U.S. Agency for International Development, and nongovernmental organizations that fund projects on fisheries reform in developing countries to monitor and evaluate progress.

Until 2001, she worked at the NationalAcademies» National Research Council over a 17 - year period, serving in several capacities — Executive Director of the Board on Sustainable Development, where she directed the Sustainability Transition Study and the Global Change Research Program; director of international organization programs for the Office of International Affairs; and Director of the Polar Research Board.